Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
about
Pharmacological management of IPFMyriad Functions of Stanniocalcin-1 (STC1) Cover Multiple Therapeutic Targets in the Complicated Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF)Update on diagnosis and treatment of idiopathic pulmonary fibrosisFirst Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.The future of the development of medicines in idiopathic pulmonary fibrosis.Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China.Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials.TGF-β signaling in the kidney: profibrotic and protective effectsFibroblast Activation Protein (FAP) Accelerates Collagen Degradation and Clearance from Lungs in Mice.Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis.Emodin ameliorates bleomycin-induced pulmonary fibrosis in rats by suppressing epithelial-mesenchymal transition and fibroblast activation.Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis.Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis.Liver fibrosis in 2015: Crucial steps towards an effective treatment.Magnetic resonance imaging with hyperpolarized agents: methods and applications.A Glimpse into the Future: Automated Quantitative Computed Tomography as a Biomarker in Idiopathic Pulmonary Fibrosis.Will novel oral formulations change the management of inflammatory bowel disease?Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications.Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways.How we will diagnose IPF in the future.The next generation of therapeutics for chronic kidney diseaseCthrc1 lowers pulmonary collagen associated with bleomycin-induced fibrosis and protects lung functionThe safety of new drug treatments for idiopathic pulmonary fibrosis.Role of Smad3 and p38 Signalling in Cigarette Smoke-induced CFTR and BK dysfunction in Primary Human Bronchial Airway Epithelial Cells.HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-β/SMAD signalling pathway.An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).House of Cards? Testing Fundamental Assumptions in Idiopathic Pulmonary Fibrosis Epidemiology.Clarity on Endpoints for Clinical Trials in Idiopathic Pulmonary Fibrosis.Measuring what matters to rare disease patients - reflections on the work by the IRDiRC taskforce on patient-centered outcome measures.Matrix biomechanics and dynamics in pulmonary fibrosis.Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres.Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge.Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.Study the past to divine the future. Confucius' wisdom doesn't work for idiopathic pulmonary fibrosis.Patient-centered Outcomes in Idiopathic Pulmonary Fibrosis Clinical Trials.Interstitial lung disease points to consider for clinical trials in systemic sclerosis.Clinical Trial Design Based on Time to Death/Progression.
P2860
Q26748808-80D00D1E-34CE-486A-8319-C8379850AC0BQ26770376-8E9055D0-621D-41F2-B42D-0E8FCEB28858Q28083702-8490BA71-5FC8-4E3F-A6DC-23EB5A8AA11BQ31112375-94C27472-B7EC-4E75-A90A-B7299CC8223EQ35785682-85487B19-1F54-44F8-A69F-CB578EAEFEF8Q35785834-033428C0-8182-46DD-BC46-3A87597C5601Q36477472-7013E653-C541-47D5-B4A1-AFD17D71B400Q36775661-D3F932D8-892D-4AA9-B151-430CEAD03326Q36778823-32F93447-3188-433A-BFC2-AE5BFC4376FFQ37345980-B40A09B2-6FF9-406B-BEF8-20FA9B22EBFDQ37360395-CC0FC34B-5D74-48C2-9CBA-CAFFE9EF9EE1Q38524352-F0EF27E2-D967-4DCE-A148-43ECBEFE05D7Q38661833-B71AB7D1-6830-42B8-A2A8-46897A7EB081Q38692388-10E0CEC1-390E-4228-8EB5-BE72F06FA21BQ38693928-1F277635-7C2C-41E4-A8C3-1501230027C5Q38734065-27D464AB-4DCC-4AD8-8C03-C96E8E84C547Q38737267-A20DD035-C4EE-496D-9A82-3453107C50BAQ38769875-F2AD641B-490E-443F-A04B-A6EB728B3EEFQ38804833-5518DA8A-1C38-43E5-8C4E-FCE762D54C93Q38812037-EC3C74F9-7D10-4940-A776-AB44C7BFEDB2Q38821078-705E4C41-A851-47D1-A3D0-8107D6335C09Q38831660-031F5E65-379D-4052-9BA4-25240C981B8AQ38845590-0CCB2D86-E1A5-4088-B402-83CE5B62CB14Q38908334-23A98A4E-DD7D-4C24-AB2C-17D715F7999DQ38929487-A559D4D2-0E66-4ED1-9DED-C2D577FC17A8Q41621094-31FF5711-5A13-44D7-8E29-F16CFB3BBE28Q42021947-B9D4A52A-04D4-46DF-9152-7C1EB9E99440Q42689952-FA63AD54-4888-428F-A9CA-F69A23960A7BQ45350235-1287E38F-79C8-43C5-A492-90BD4FF7B5EDQ46863202-3C26DCD0-FE46-4E80-B2D5-2C1D7180C13BQ47102105-4143F98C-8810-41BA-85FF-578F0B49D22BQ47221688-4595B3D6-4295-4A1C-BFFA-22FFCB096B85Q47524535-955D78F1-F758-4F42-BEE9-DBE1D3B769ACQ47656318-0B06FBFC-69F8-4557-9A1D-86AA8174123DQ47680958-B02C35BC-80DB-49F9-8B9A-8C830D5367CCQ47791471-FD6BD71F-2B25-4739-AF4B-D37B9A453D87Q48149114-2FA3CABE-1FFF-4A9C-B658-4F0711D40277Q48284711-BBA06467-EEDF-4221-922B-92A68BD993DDQ49384982-498B0F54-AE17-4901-B488-AC56D256BF45Q51810369-C2AD9711-B452-41DC-B034-5F1F0A01FF3B
P2860
Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Forced vital capacity in idiop ...... of pirfenidone and nintedanib.
@en
type
label
Forced vital capacity in idiop ...... of pirfenidone and nintedanib.
@en
prefLabel
Forced vital capacity in idiop ...... of pirfenidone and nintedanib.
@en
P356
P1476
Forced vital capacity in idiop ...... of pirfenidone and nintedanib.
@en
P2093
Badrul A Chowdhury
Banu A Karimi-Shah
P304
P356
10.1056/NEJMP1500526
P407
P577
2015-03-01T00:00:00Z